Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022
Swedish Firm Names New Strategic Targets
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.
You may also be interested in...
Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
Xbrane Biopharma has celebrated after being granted two Swedish patents covering its “high-yield” protein expression platform that the biosimilars specialist expects to act as the basis for international applications.
Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane biosimilar ranibizumab asset was submitted to the European Medicines Agency by co-development and commercialization partner Stada.